OptiScan Biomedical
OptiScan Biomedical develops glucose monitoring systems that help healthcare providers manage patient glucose levels in clinical settings, targeting the inpatient continuous glucose monitoring segment.
- Company typePrivate
- Founded1994
- HeadquartersHayward, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What OptiScan Biomedical does
OptiScan Biomedical is a privately held medical device company headquartered in Hayward, California, founded in 1994. The company develops glucose monitoring systems intended to assist healthcare providers in managing patient glucose levels in clinical settings, positioning it in the inpatient continuous glucose monitoring (CGM) segment — distinct from consumer-focused CGM manufacturers.
The company has raised approximately $165 million across at least seven disclosed funding rounds between 2005 and 2019, drawing a diverse institutional and strategic investor base that includes Johnson & Johnson Development Corporation, MedVenture Associates, Morgenthaler Ventures, Wexford Capital, JPMorgan Partners, NGN Capital, Mitsui Global Investment, Wellcome Trust, Oakwood Medical Investors, EGS Healthcare Capital Partners, and Prism Venture Management. Its long R&D-to-commercialization cycle and sustained capital deployment are consistent with a Class II/III medical device requiring multi-year FDA clinical validation. The company operates with a 51-100 employee headcount.
Peter R. Rule serves as Chief Executive Officer. With no disclosed revenue, customer accounts, or product launch dates in the available data, the company's go-to-market is presumed to follow a capital equipment + recurring consumables model targeting hospital ICUs and surgical settings, though commercial scale remains unverified.
OptiScan Biomedical firmographics
Firmographics- Name
- OptiScan Biomedical
- Website
- https://optiscancorp.com
- Company type
- Private
- Founded year
- 1994
- Headcount range
- 51–100 employees
- Short description
- OptiScan Biomedical develops glucose monitoring systems that help healthcare providers manage patient glucose levels in clinical settings, targeting the inpatient continuous glucose monitoring segment.
- Ownership category
- akta.pro rank
OptiScan Biomedical industry classification
Industry- Product category
- Continuous Glucose Monitoring Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate) (HLAHAOAB)
- akta.pro secondary industries
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
Keywords
Where OptiScan Biomedical is headquartered
LocationHeadquarters
- HQ city
- Hayward
- HQ country
- United States
- HQ region
- North America
Markets served
OptiScan Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
OptiScan Biomedical product offering
Product offeringCore offering
OptiScan Biomedical develops and manufactures glucose monitoring systems intended to assist healthcare providers in measuring and managing patient glucose levels in clinical settings. The company's systems are designed for hospital-based, bedside patient monitoring rather than personal consumer use.
Differentiator
Problem solved
Functional benefit
Products and services
- Glucose Monitoring System
Companies that use OptiScan Biomedical
Customer profileIdeal customer profiles1 record
OptiScan Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
OptiScan Biomedical partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
OptiScan Biomedical competitors and assessment
Company assessmentBroad incumbents
- Dexcom: Dexcom is the dominant continuous glucose monitor (CGM) manufacturer, primarily consumer-facing but increasingly expanding into inpatient and hospital use cases. It competes with OptiScan for glucose monitoring mindshare and hospital formulary adoption.
- Roche Diagnostics: Roche is a global leader in hospital blood glucose meters and centralized lab glucose testing through its cobas and Accu-Chek lines. It competes with OptiScan across hospital POC glucose measurement and integrated clinical chemistry workflows.
- Abbott Diabetes Care: Abbott's FreeStyle Libre is the leading consumer CGM and is actively expanding into hospital, surgical, and critical care settings. As a broad incumbent with global scale, Abbott represents a primary competitive threat to OptiScan's clinical positioning.
- Medtronic Diabetes: Medtronic offers the Guardian CGM and the MiniMed automated insulin delivery system, and has pursued hospital glucose management initiatives. It overlaps with OptiScan in clinical glucose monitoring and integrated insulin delivery.
Emerging players
- Senseonics Holdings: Senseonics develops the Eversense implantable CGM, an emerging long-duration CGM technology with potential hospital applications. It overlaps with OptiScan's clinical glucose monitoring focus from a different technological approach.
- Nemaura Medical: Nemaura is developing non-invasive and continuous glucose monitoring technologies (sugarBEAT) targeting consumer and clinical applications. It is an emerging competitor whose success would erode OptiScan's positioning in glucose monitoring.
Direct peers
- Nova Biomedical: Nova Biomedical manufactures point-of-care and hospital blood gas, chemistry, and glucose analyzers used in ICUs and clinical labs. It directly overlaps with OptiScan's provider-facing glucose monitoring focus and competes for the same hospital capital equipment budgets.
- Ascensia Diabetes Care: Ascensia (spun out of Bayer's diabetes care business and now owned by PHC Holdings) markets the CONTOUR line of blood glucose monitoring systems, including healthcare professional versions. It directly competes with OptiScan in glucose monitoring for providers and patients.
- LifeScan: LifeScan (historically part of Johnson & Johnson, which is also an OptiScan investor) markets the OneTouch line of blood glucose monitoring systems, including professional and hospital use cases. It is a directly comparable peer in glucose monitoring devices for providers.
Regional players
- Ypsomed: Ypsomed is a Swiss-based diabetes care company that manufactures insulin delivery systems and blood glucose monitoring accessories, primarily serving European markets. It overlaps with OptiScan in diabetes care devices and consumables.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
OptiScan Biomedical social profiles
Digital presenceOptiScan Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
OptiScan Biomedical leadership team
Management profileNumber of profiles
Profiles1 record
OptiScan Biomedical funding detail
Funding detailFunding overview
Funding rounds8 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OptiScan Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OptiScan Biomedical
What does OptiScan Biomedical do?
OptiScan Biomedical develops and manufactures glucose monitoring systems intended to assist healthcare providers in measuring and managing patient glucose levels in clinical settings. The company's systems are designed for hospital-based, bedside patient monitoring rather than personal consumer use.
When was OptiScan Biomedical founded?
OptiScan Biomedical was founded in 1994. It employs 51 to 100 people.
Where is OptiScan Biomedical based?
OptiScan Biomedical is headquartered in Hayward, United States, in the North America region.
Who are OptiScan Biomedical's main competitors?
Broad incumbents on record are Dexcom, Roche Diagnostics, Abbott Diabetes Care and Medtronic Diabetes. Emerging players are Senseonics Holdings and Nemaura Medical. Direct peers are Nova Biomedical, Ascensia Diabetes Care and LifeScan. Ypsomed is listed as a regional player.
Does OptiScan Biomedical have an API?
No public API is recorded for OptiScan Biomedical.
What industry is OptiScan Biomedical in?
OptiScan Biomedical's product category is Continuous Glucose Monitoring Medical Devices. Its primary akta.pro industry code is HLAHAOAB, Blood Glucose & Metabolic POCT (Glucose, Ketones, Lactate), with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 334510 and its SIC code is 3845.